Women’s Representation in CVD Drug Trials Varies
Representation of women is low for cardiovascular disease clinical trials in certain conditions.
Therapies
Nebulized Glycopyrrolate Improves Lung Function in Severe COPD With CV Risk Factors
Nebulized glycopyrrolate improves lung function and patient-reported outcomes in patients with moderate to very severe COPD.
Anticoagulant Effect of Dabigatran Successfully Reversed in Emergency Situations
Idarucizumab can effectively reverse the anticoagulant effect of dabigatran.
Mexiletine Reduces Arrhythmic Events for Long QT Syndrome Type 3 Patients
Mexiletine significantly reduced life-threatening arrhythmic events in long QT syndrome type 3 patients.
Statin Therapy Does Not Prevent Acute Kidney Injury Following Cardiac Surgery
Acute kidney injury occurred in 20.8% of the atorvastatin group and 19.5% of the placebo group, indicating that initiating perioperative statin therapy does not prevent AKI following cardiac surgery.
Early Beta-Blocker Administration Reduces In-Hospital Mortality in Acute Coronary Syndromes
Researchers found that when oral beta-blockers were administered less than 24 hours after hospital admission, in-hospitality mortality and severe left ventricular dysfunction were both reduced.
N-3 Polyunsaturated Fatty Acids Reduces Risk of All-Cause Mortality in Myocardial Infarction
N-3 polyunsaturated fatty acid use is associated with reduced risk of all-cause mortality and recurrent acute myocardial infarction.
ACE Inhibitors May Not Be as Effective in Black Patients
Black patients may be less response to antihypertensive treatment with angiotensin-converting enzyme inhibitors than white patients.
FreezeAF: Cryoballoon Noninferior to Radiofrequency Ablation for Paroxysmal Atrial Fibrillation
Recent trials have shown that cryoballoon catheter ablation has demonstrated success in treating atrial fibrillation among 74% of patients, presenting an alternative to traditional radiofrequency ablation.
FDA Approves Entresto for Systolic Heart Failure
Intended to reduce risk of cardiovascular death and heart failure-related hospitalization, the FDA has approved Entresto.
- Loading...
Loading...
Next post in Heart Failure
Loading... 
Loading...